Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens

Engineering of relevant photodynamic processes through structural modifications of metallotetrapyrrolic photosensitizers

“…These photosensitisers are sulfonic acid derivatives of halogenated tetraphenyl bacteriochlorins and showed tumor:muscle and tumor:skin ratios in the 3-11 range [47,[98][99][100]. Our the most promising photosensitizer was named redaporfin (also referred by the code names F 2 BMet and LUZ11) and its PDT efficacy was revealed in the treatment of mice with subcutaneously implanted CT26 colon carcinoma, light-pigmented S91 melanoma and highly pigmented B16 F10 melanoma tumors [14,20,203]. It is currently completing a Phase II clinical trial for advanced head and neck cancer.…”

“…Gomer and coauthors reported a tumor margin of 1-2 mm for PDT and a resection margin of 4 mm in surgical excision of the same tumors, whereas Mroz et al applied tumor margins of 2-3 mm [27,43]. We have recently proven that the increase of the illuminated surface improves the PDT outcome [14]. For ca.…”

“…The photosensitizer is administered into the organism and after a certain time (drug-tolight interval; DLI) is excited with the light of an appropriate wavelength matching a peak of its electronic absorption spectrum [14]. As the result of deactivation of the PS excited states (PS*), two main photochemical processes play a key role in PDT: photoinduced electron transfer or energy transfer from PS* to another molecule, e.g.…”

“…A most powerful factor in the elimination of cancers and assessment of tumor response to therapy seems to be the activation of the immune system to recognize and eliminate cancer cells. This anticancer mechanism may be eventually used to improve photodynamic therapy efficacy and safety, and can open a promising path to a new modality of cancer treatment [14]. Immunological aspects of antitumor PDT will be discussed in detail later in this work.…”

Mechanistic studies on versatile metal-assisted hydrogen peroxide activation processes for biomedical and environmental incentives

“…It is an example of how the dynamics of the interaction between light, a photosensitizer and oxygen can be tuned to increase therapeutic efficacy. The fact that redaporfin interacts with molecular oxygen both through type I and type II photoreactions makes it versatile in the treatment of a variety of cancer cells and tumors, such as melanoma [233,234,242], lung adenocarcinoma [230,232] and colon carcinoma [275][276][277]. It is currently in phase II clinical trials for head and neck tumors.…”